TY  - JOUR
AU  - Martin, M
AU  - Zielinski, C
AU  - Ruiz-Borrego, M
AU  - Carrasco, E
AU  - Turner, N
AU  - Ciruelos, E M
AU  - Muñoz, M
AU  - Bermejo, B
AU  - Margeli, M
AU  - Anton, A
AU  - Kahan, Z
AU  - Csoszi, T
AU  - Casas, M I
AU  - Murillo, L
AU  - Morales, S
AU  - Alba, E
AU  - Gal-Yam, E
AU  - Guerrero-Zotano, A
AU  - Calvo, L
AU  - de-la-Haba-Rodriguez, J
AU  - Ramos, M
AU  - Alvarez, I
AU  - Garcia-Palomo, A
AU  - Huang-Bartlett, C
AU  - Koehler, M
AU  - Caballero, R
AU  - Corsaro, M
AU  - Huang, X
AU  - Garcia-Saenz, J A
AU  - Chacon, J I
AU  - Swift, C
AU  - Thallinger, C
AU  - Gil-Gil, M
PY  - 2020
DO  - 10.1016/j.annonc.2020.12.013
UR  - http://hdl.handle.net/10668/16888
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that of chemotherapy...
LA  - en
PB  - Elsevier
KW  - HER2-negative
KW  - Capecitabine
KW  - Endocrine therapy
KW  - Hormone receptor-positive
KW  - Metastatic breast cancer
KW  - Palbociclib
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Aromatase Inhibitors
KW  - Breast Neoplasms
KW  - Capecitabine
KW  - EGF Family of Proteins
KW  - Humans
KW  - Piperazines
KW  - Pyridines
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
TI  - Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
TY  - research article
VL  - 32
ER  -